非注射胰岛素市场 - 2018-2028 年全球产业规模、份额、趋势、机会与预测，按产品、配销通路、地区、竞争细分

2022年全球非注射胰岛素市场估值达到26.9亿美元，并有望在整个预测期内大幅增长，预计将保持9.10%的强劲复合年增长率（CAGR），预计将达到45.1亿美元2028年。这个充满活力的细分市场涵盖了多种专为无需注射而给药的胰岛素製剂。这些创新的替代方案迎合了糖尿病患者的需求，解决了与传统注射方法和注射过敏反应相关的挑战。非注射胰岛素的选择包括口服、吸入、贴片和新兴的给药方法。

主要市场驱动因素

• 1.改善血糖控制：全球非注射胰岛素市场从血糖控制的进步中受益匪浅。此类别包括无需传统针头注射的胰岛素输送方法，包括吸入胰岛素、口服胰岛素和经皮胰岛素输送系统。血糖控制的一致性是糖尿病管理的主要挑战。由于不适、疼痛和针头焦虑，注射胰岛素可能会阻碍患者遵守规定的胰岛素治疗方案。非注射胰岛素方法提供了更方便、侵入性更小的替代方案，有可能提高患者的依从性。改善糖尿病管理和血糖控制可降低併发症和住院的风险。非注射胰岛素方法，特别是那些容易给药的方法，可以鼓励早期介入糖尿病管理。早期开始胰岛素治疗可以改善血糖控制，减缓疾病进展，并带来更好的长期结果，同时降低与糖尿病相关的医疗费用。非注射胰岛素方法扩大了糖尿病患者的治疗选择，特别是那些厌恶针头或身体限制的患者，可能会增强血糖控制。这些方法可以吸引新的患者群体，这些患者先前因担心注射而犹豫是否开始胰岛素治疗，从而促进市场成长。

市场概况
预测期	2024-2028
2022 年市场规模	26.9亿美元
2028 年市场规模	45.1亿美元
2023-2028 年复合年增长率	9.10%
成长最快的细分市场	药局
最大的市场	北美洲

• 2.不断增长的糖尿病人口：不断增长的糖尿病人口对全球非注射胰岛素市场产生了重大影响。以血糖水平升高为特征的糖尿病在全球范围内的盛行率不断上升，推动了对有效且方便的治疗方法（包括非注射胰岛素）的需求。随着糖尿病人口的持续增长，对包括胰岛素治疗在内的多种糖尿病管理解决方案的需求不断增加。非注射胰岛素方法为那些不愿意或无法使用传统注射胰岛素的人提供了替代方案。对方便且患者友善的治疗的需求增加有助于市场扩张。非注射胰岛素方法适合更广泛的患者，包括那些不愿意打针或对注射有困难的患者。不断增长的糖尿病人口跨越了不同的年龄层和背景，使得吸入型或口服胰岛素等非注射胰岛素产品在不同人群中更容易被接受。遵守糖尿病治疗计划对于实现有效的血糖控制和避免併发症至关重要。然而，许多醣尿病患者由于害怕针头或不方便而难以坚持注射胰岛素治疗方案。非注射胰岛素方法提高了便利性和易用性，有可能促进更好的依从性和结果。随着糖尿病人口的快速增长，早期介入和预防措施变得越来越重要。非注射胰岛素选择可以鼓励个人更早开始胰岛素治疗，从而加强血糖控制。早期介入可以延迟或预防糖尿病相关併发症，控制医疗费用并提高患者的生活品质。糖尿病盛行率的不断上升为创新糖尿病管理产品提供了巨大的市场机会，推动了研究、开发和商业化工作，推动了市场成长。
• 3.医药产业投资：医药产业投资在影响全球非注射胰岛素市场的成长轨迹方面发挥关键作用。这些投资涵盖与非注射胰岛素产品相关的研发 (R&D)、临床试验、製造、行销和分销工作。製药公司分配大量资源进行研发，并专注于创新的非注射胰岛素输送方法。这些投资推动了对新技术、配方和给药途径的探索，以提高胰岛素治疗的便利性和患者友善性。这些投资所取得的进展透过引入新颖有效的治疗方案推动了市场扩张。製药业的投资刺激了非注射胰岛素领域的创新，旨在创造出具有更高功效、安全性和患者体验的产品。创新可能包括更精确的给药机制、缓释製剂和优化的递送系统。这些进步引起了医疗保健专业人员和患者的关注，促进了市场的采用和成长。严格的临床试验是将新药品推向市场的关键一步。业界对这些试验的投资验证了非注射胰岛素方法的安全性和有效性，为监管部门批准提供了必要的资料。积极的试验结果增强了医学界的信心，促进了这些产品的更广泛采用并促进了市场成长。产业投资通常延伸到教育计划，旨在向医疗保健专业人员和患者介绍非注射胰岛素方法。教育计划可帮助医疗保健提供者做出明智的治疗决策，并使患者能够选择合适的选择。意识的增强推动了更高的采用率，对市场成长有正面影响。

主要市场挑战

• 1.功效和安全性问题：功效和安全性问题可能会对全球非注射胰岛素市场的成长构成障碍。虽然非注射胰岛素方法提供了传统注射的便利替代方案，但解决这些问题对于获得医疗保健专业人员、监管机构和患者的信任至关重要。当临床证据不足，无法证明非注射胰岛素方法可提供与注射胰岛素相当的一致且可靠的血糖控制时，就会出现疗效问题。如果没有明确的证据证明其有效性，医疗保健专业人员和患者可能会犹豫是否转向非注射疗法。如果非注射胰岛素产品产生不一致或不可预测的血糖水平，患者和医疗保健提供者可能会认为它们不如注射胰岛素可靠，从而损害对糖尿病管理的长期信任。安全性问题包括不良反应、副作用以及与其他药物的潜在交互作用。确保这些产品的安全对于获得监管批准以及在患者和医疗保健专业人员之间建立信任至关重要。非注射胰岛素方法，特别是新型输送技术的长期影响可能仍不完全清楚。患者和医疗保健提供者可能会对长期使用后出现的潜在併发症表示担忧，从而影响他们采用这些方法的意愿。
• 2.成本和承受能力：成本和承受能力是阻碍全球非注射胰岛素市场成长的重要因素。虽然非注射胰岛素方法在便利性和患者友善性方面具有优势，但与传统的注射胰岛素相比，它们有时可能需要更高的成本。非注射胰岛素方法通常涉及更复杂的技术、研究和开发，导致生产成本升高。因此，非注射胰岛素产品的初始购买价格可能会超过注射胰岛素。这种成本差异可能会阻碍患者和医疗保健提供者选择非注射疗法。保险范围和报销政策可能无法完全涵盖非注射胰岛素方法的费用，使患者承担可能难以负担的自付费用。这种覆盖范围的缺乏构成了一个重大障碍，阻止患者获得这些替代品并抑制市场成长。糖尿病患者经常面临与药物、监测设备、医生就诊等相关的持续医疗费用。将非注射胰岛素产品成本纳入这些费用可能会对患者造成经济压力，迫使他们选择更经济的替代品。一些先进的非注射胰岛素产品，尤其是更复杂的产品，在医疗资源有限的低收入地区可能仍然无法获得或负担不起。这种差异可能会导致健康不平等并阻碍全球市场的扩张。竞争格局包括具有长期市场地位的成熟注射胰岛素产品。新的非注射替代品可能需要在价格上竞争以确保市场份额，如果生产成本较高，这可能会具有挑战性。

主要市场趋势

• 1.个人化治疗方法：个人化治疗方法使医疗保健提供者能够根据患者的病史、生活方式和偏好选择最合适的非注射胰岛素方法。这种量身定制的方法提高了治疗依从性和成功结果的可能性，推动了非注射方法的采用。当患者参与治疗计划并且可以选择符合自己喜好的选项时，他们更有可能对自己的照护感到满意。非注射胰岛素方法提供便利且对患者友好，有助于提高患者满意度，促进市场成长。患者可能对传统注射心存疑虑，例如针头焦虑或害怕疼痛。个人化治疗方法可以透过提供非注射胰岛素替代品来解决这些问题，这可能会提高患者的舒适度和接受度。不同的年龄层有不同的偏好和要求。例如，老年人可能会因灵活性下降而难以进行注射，而幼儿可能会难以接受传统的胰岛素注射。非注射胰岛素方法可以针对这些特定年龄的挑战进行定制，从而扩大市场范围。个人化方法考虑患者的生活方式，包括日常生活、工作时间表和饮食习惯。符合患者生活方式的非注射胰岛素选择更有可能被采用，从而推动市场成长。糖尿病管理对于预防併发症至关重要。个人化治疗计划可以针对特定的危险因素，确保患者接受最有效的治疗，以避免与血糖控制不良相关的併发症。这种方法鼓励采用满足患者需求的非注射胰岛素方法。
• 2.监管和报销进展：监管机构在确保医疗产品（包括非注射胰岛素）的安全性和有效性方面具有重大影响力。专为创新给药方法设计的监管途径的进步可以加快审批过程，从而激励製药公司投资非注射胰岛素的研究和开发。简化的监管途径加速了产品进入，激励製造商投资于非注射胰岛素的研发。强而有力的监管指南为製造商提供了清晰的产品开发和临床试验路线图，确保在向市场推出创新产品的同时符合特定标准。监管机构采用基于风险的监督，根据非注射胰岛素方法的独特属性定制评估流程，平衡严格的安全标准与这些输送系统带来的独特优势和挑战。监管的进步允许扩大非注射胰岛素方法的适应症，并扩大了其潜在的患者基础。获得不同糖尿病类型或特定患者群体的批准可以扩大市场范围。报销的进步提高了非注射胰岛素方法的覆盖范围，激励医疗保健提供者开出这些选择。增强的报销政策减少了患者的经济障碍，使非注射胰岛素更容易获得併刺激了采用。製药公司和付款人（保险公司和政府医疗保健计划）之间的合作可以达成互利的协议。协商非注射胰岛素产品的定价和报销条款可确保患者负担得起，从而促进采用和市场扩张。监管和报销政策的国际一致性简化了多个地区的同时市场准入，减少了障碍并加速了全球非注射胰岛素产品的扩张。

细分市场洞察

类型洞察：在产品类别中，药丸细分市场可望在整个预测期内实现大幅市场成长。有几个因素促成了这种成长，包括：

许多醣尿病患者对针头厌恶或恐惧：口服胰岛素药丸提供了一种更舒适和熟悉的药物输送方法，减少了胰岛素治疗的心理障碍。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球非注射胰岛素市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（药丸、喷雾等）
  • 依配销通路（医院药局、网路药局、药局）
  • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
  • 按公司划分 (2022)
• 市场地图
  • 按产品分类
  • 按配销通路
  • 按地区

第 6 章：北美非注射胰岛素市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（药丸、喷雾等）
  • 依配销通路（医院药局、网路药局、药局）
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲非注射胰岛素市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（药丸、喷雾等）
  • 依配销通路（医院药局、网路药局、药局）
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太非注射胰岛素市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（药丸、喷雾等）
  • 依配销通路（医院药局、网路药局、药局）
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲非注射胰岛素市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（药丸、喷雾等）
  • 依配销通路（医院药局、网路药局、药局）
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲非注射胰岛素市场前景

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（药丸、喷雾等）
  • 依配销通路（医院药局、网路药局、药局）
  • 按国家/地区
• MEA：国家分析
  • 南非非注射胰岛素
  • 沙乌地阿拉伯非注射胰岛素
  • 阿联酋非注射胰岛素

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球非注射胰岛素市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 产品供应
• 最近的发展
• 财务（据报导）
• 主要人员
• SWOT分析
  • Midatech Pharma Plc
  • Shreya Life Sciences Pvt. Ltd.
  • Boston Therapeutics, Inc.
  • Coromed, Inc.
  • Diabetology Ltd.
  • Emisphere Technologies, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Diasome Pharmaceuticals, Inc.
  • Generex Biotechnology Corp.
  • Biodel, Inc.

第 16 章：策略建议

Global Non-Injectable Insulin Market is anticipated to project robust growth in the forecast period. The non-injectable insulin market comprises various insulin formulations designed for administration without injections. These alternatives offer options for individuals with diabetes who face challenges with conventional injection techniques or have allergies to injections. Non-injectable options include oral, inhalable, patches, and other emerging delivery methods.

Key Market Drivers

Improved Glycemic Control

Improved glycemic control can have a significant influence on the growth of the global non-injectable insulin market. Non-injectable insulin refers to insulin delivery methods that do not involve traditional needle injections, such as inhalable insulin, oral insulin, and transdermal insulin delivery systems. One of the main challenges in diabetes management is maintaining consistent glycemic control. Injectable insulin may lead to discomfort, pain, and needle anxiety, which can deter some patients from adhering to their prescribed insulin regimen. Non-injectable insulin methods offer more convenient and less invasive options, potentially increasing patient compliance. When patients can manage their diabetes more effectively, it leads to improved glycemic control, reducing the risk of complications and hospitalizations. Non-injectable insulin methods, especially those that are easier to administer and less intimidating, can encourage earlier intervention in diabetes management. By starting insulin therapy earlier in the disease progression, patients can achieve better glycemic control and slow down the progression of the disease. This can lead to better long-term outcomes and reduced healthcare costs associated with diabetes-related complications. Improved glycemic control with non-injectable insulin methods offers a wider range of treatment options for individuals with diabetes. This is especially important for patients who may have a fear of needles or struggle with injections due to physical limitations. By offering multiple routes of administration, healthcare providers can tailor treatment plans to individual patient needs, potentially leading to better glycemic control. Improved glycemic control achieved through non-injectable insulin methods can attract new patient populations, including those who may have been hesitant to start insulin therapy due to the fear of injections. This expansion of the patient base can contribute to market growth.

Growing Diabetic Population

The growing diabetic population has a substantial influence on the growth of the global non-injectable insulin market. Diabetes is a chronic condition characterized by high blood sugar levels, and its prevalence has been increasing globally. This rise in the number of people with diabetes directly impacts the demand for effective and convenient treatment options, such as non-injectable insulin. As the diabetic population continues to grow, the demand for various diabetes management solutions, including insulin therapies, also increases. Non-injectable insulin methods provide alternative options for those who may be reluctant or unable to use traditional injectable insulin. This increased demand for more convenient and patient-friendly treatment options contributes to the growth of the non-injectable insulin market. Non-injectable insulin methods can cater to a broader range of patients, including those who are hesitant to use needles or have difficulty with injections. The growing diabetic population includes individuals from diverse backgrounds and age groups. Non-injectable insulin products, such as inhalable insulin or oral insulin, provide options that are more acceptable to different segments of the population, thus expanding the potential patient base. Adherence to diabetes treatment plans is essential for achieving good glycemic control and preventing complications. However, many diabetic patients struggle with adhering to injectable insulin regimens due to factors like fear of needles or inconvenience. Non-injectable insulin methods offer improved convenience and ease of use, potentially leading to better treatment adherence and outcomes. With a larger diabetic population, there is a greater emphasis on early intervention and preventive measures. Non-injectable insulin options can encourage individuals to start insulin therapy earlier in their disease progression, leading to better glycemic control. Early intervention can potentially delay or prevent the onset of diabetes-related complications, reducing healthcare costs and improving patients' quality of life. The increasing prevalence of diabetes has led to a significant market opportunity for innovative diabetes management products. Manufacturers and researchers are motivated to develop new and improved non-injectable insulin technologies to meet the diverse needs of the growing diabetic population. This drives investment in research, development, and commercialization of these products, thereby fostering market growth.

Pharmaceutical Industry Investment

Pharmaceutical industry investments play a significant role in influencing the growth of the global non-injectable insulin market. These investments encompass research and development (R&D), clinical trials, manufacturing, marketing, and distribution efforts related to non-injectable insulin products. Pharmaceutical companies allocate substantial resources to R&D for developing innovative non-injectable insulin delivery methods. These investments go into exploring new technologies, formulations, and administration routes that make insulin therapy more convenient and patient-friendly. Advancements resulting from these investments contribute to the expansion of the market by introducing novel and effective treatment options. Pharmaceutical industry investments drive innovation in the non-injectable insulin sector. Companies aim to create products with improved efficacy, safety, and patient experience. Innovations could include more accurate dosing mechanisms, longer-lasting formulations, and optimized delivery systems. Such advancements attract healthcare professionals and patients, boosting market adoption and growth. Rigorous clinical trials are a crucial part of bringing new pharmaceutical products to market. Industry investments in these trials validate the safety and efficacy of non-injectable insulin methods, providing the data needed for regulatory approvals. Positive trial results build confidence in the medical community and encourage wider adoption of these products, driving market growth. Industry investments often extend to educational initiatives aimed at informing healthcare professionals and patients about non-injectable insulin methods. Educational programs help healthcare providers make informed treatment decisions and empower patients to choose suitable options. Improved awareness leads to higher adoption rates, positively impacting market growth.

Key Market Challenges

Efficacy and Safety Concerns

Efficacy and safety concerns can indeed hinder the growth of the global non-injectable insulin market. While non-injectable insulin methods offer convenient and patient-friendly alternatives to traditional injections, addressing these concerns is essential to gain the trust of healthcare professionals, regulators, and patients. Efficacy concerns arise when there is insufficient clinical evidence to demonstrate that non-injectable insulin methods provide consistent and reliable blood sugar control comparable to injectable insulin. Healthcare professionals and patients may be hesitant to switch to non-injectable options without clear evidence of their effectiveness. If non-injectable insulin products result in inconsistent or unpredictable blood sugar levels, patients and healthcare providers may view them as less reliable than injectable insulin. This can lead to skepticism about their long-term effectiveness in managing diabetes, inhibiting market growth. Safety concerns related to non-injectable insulin methods encompass issues such as adverse reactions, side effects, and potential interactions with other medications. Ensuring the safety of these products is critical to gaining regulatory approvals and building trust among patients and healthcare professionals. The long-term effects of non-injectable insulin methods may not be fully understood, especially for novel delivery technologies. Healthcare providers and patients may worry about potential complications that could arise after extended use, impacting the willingness to adopt these methods.

Cost and Affordability

Cost and affordability are significant factors that can hinder the growth of the global non-injectable insulin market. While non-injectable insulin methods offer advantages in terms of convenience and patient-friendliness, they can sometimes come with higher costs compared to traditional injectable insulin. Non-injectable insulin methods often involve more complex technology, research, and development, which can lead to higher production costs. As a result, the initial purchase price of non-injectable insulin products can be higher than that of injectable insulin. This cost difference may discourage patients and healthcare providers from choosing non-injectable options. Insurance coverage and reimbursement policies may not fully cover the costs of non-injectable insulin methods. Patients may face out-of-pocket expenses that they find challenging to afford. This lack of coverage can be a significant barrier, preventing patients from accessing these options and inhibiting market growth. Individuals with diabetes often have ongoing healthcare expenses related to medications, monitoring equipment, doctor visits, and more. Adding the cost of non-injectable insulin methods to these expenses can create a significant financial burden for patients, leading them to opt for more affordable alternatives. Non-injectable insulin products, especially the more advanced ones, may not be accessible or affordable in low-income countries with limited healthcare resources. This can result in health disparities and hinder the global expansion of the market. The competitive landscape includes established injectable insulin products that have been on the market for a long time. New non-injectable options may need to compete on pricing to gain market share, which could be challenging if production costs are higher.

Key Market Trends

Personalized Treatment Approaches

Personalized approaches enable healthcare providers to choose the most suitable non-injectable insulin method based on a patient's medical history, lifestyle, and preferences. This tailored approach increases the likelihood of treatment adherence and successful outcomes, driving the adoption of non-injectable methods. When patients have a say in their treatment plans and can choose options that align with their preferences, they are more likely to be satisfied with their care. Non-injectable insulin methods that offer convenience and patient-friendliness contribute to higher patient satisfaction and the growth of the market. Patients may have concerns about traditional injections, such as needle anxiety or fear of pain. Personalized treatment approaches can address these concerns by offering non-injectable insulin alternatives, which can lead to greater patient comfort and acceptance. Different age groups have varying preferences and needs. For example, elderly individuals may struggle with injections due to reduced dexterity, and young children may have difficulties with traditional insulin injections. Non-injectable insulin methods can be tailored to these age-specific challenges, expanding the market's reach. Personalized approaches consider patients' lifestyles, such as their daily routines, work schedules, and dietary habits. Non-injectable insulin options that align with patients' lifestyles are more likely to be adopted, leading to market growth. Diabetes management is crucial to prevent complications. Personalized treatment plans can target specific risk factors, ensuring that patients receive the most effective treatment to prevent complications associated with poor glycemic control. This approach encourages the adoption of non-injectable insulin methods that suit the patient's needs.

Regulatory and Reimbursement Advancements

Regulatory agencies play a crucial role in ensuring the safety and efficacy of medical products, including non-injectable insulin. Advancements in regulatory pathways that specifically address innovative delivery methods can expedite the approval process. A faster regulatory pathway encourages manufacturers to invest in non-injectable insulin research and development, leading to quicker market entry. Clear and supportive regulatory guidelines for non-injectable insulin methods provide manufacturers with a roadmap for product development and clinical trials. These guidelines ensure that developers meet specific standards while bringing innovative products to market, fostering innovation and growth. Regulatory agencies adopting risk-based oversight can tailor their evaluation processes to the unique characteristics of non-injectable insulin methods. This approach ensures that rigorous safety standards are met while accommodating the specific benefits and challenges of these delivery systems. Regulatory advancements that allow for expanded indications for non-injectable insulin methods increase their potential patient populations. For example, gaining approval for different types of diabetes or specific patient groups can significantly broaden the market reach. Reimbursement advancements that offer better coverage for non-injectable insulin methods encourage healthcare providers to prescribe these options. Improved reimbursement policies reduce financial barriers for patients, making non-injectable insulin more accessible and encouraging adoption. Collaboration between pharmaceutical companies and payers (insurance providers, government healthcare programs) can lead to mutually beneficial agreements. Negotiating pricing and reimbursement terms for non-injectable insulin products ensures that they are affordable for patients, driving adoption and market expansion. International alignment of regulatory and reimbursement policies can facilitate simultaneous market access in multiple regions. This harmonization reduces barriers and accelerates the global expansion of non-injectable insulin products.

Segmental Insights

Type Insights

Based on the Product, the pills segment is anticipated to witness substantial market growth throughout the forecast period. This growth can be attributed to multiple factors, such as Many individuals with diabetes have an aversion to needles or injections. Oral insulin pills offer a more comfortable and familiar form of medication delivery, reducing the psychological barrier to insulin therapy. This increased patient acceptance can lead to higher adoption rates and market growth. The convenience of taking an insulin pill compared to an injection can enhance treatment adherence. Patients may be more likely to follow their prescribed treatment plan consistently when it involves a simple and easy-to-take pill. Improved adherence contributes to better glycemic control and overall patient outcomes. Oral insulin pills can encourage early intervention in diabetes management. Individuals who are hesitant to start injectable insulin therapy might be more open to trying oral pills. Early intervention can lead to better blood sugar control and prevention of complications, driving market growth. Oral insulin pills can attract a wider patient base, including those who were previously resistant to insulin therapy due to injection-related fears or concerns. This expansion of the patient population can contribute to market growth. Pills empower patients to take charge of their diabetes management independently. Patients can easily carry and administer their medication without the need for medical personnel or specialized equipment, leading to greater patient empowerment and engagement.

End Use Insights

Based on the end-use segment, the Drug Stores segment has been the dominant force in the market. Drug stores are often conveniently located in urban and suburban areas, making them easily accessible to patients. This accessibility ensures that non-injectable insulin products are readily available to a broad patient population. Pharmacists at drug stores are trained healthcare professionals who can provide patients with information about non-injectable insulin options. They can explain how these products work, their benefits, and administration techniques, enhancing patient awareness and understanding. Drug stores are essential points for patients to pick up their prescribed medications, including non-injectable insulin products. Pharmacists can guide patients on proper usage, storage, and potential side effects, promoting adherence and positive treatment outcomes. Some non-injectable insulin products may be available over-the-counter, allowing patients to purchase them without a prescription. Drug stores can stock these OTC options, giving patients greater autonomy in managing their diabetes. Some drug stores offer health screenings, including blood glucose testing. Pharmacists can use these opportunities to educate patients about non-injectable insulin methods and encourage them to consider these alternatives. Drug stores can actively promote non-injectable insulin options through in-store displays, brochures, and informational sessions. This promotion raises patient awareness and encourages them to explore these alternatives.

Regional Insights

North America, specifically the Non-Injectable Insulin Market, dominated the market in 2022, primarily due to North America, particularly the United States and Canada, boasts advanced healthcare systems, research institutions, and pharmaceutical industries. This infrastructure supports the development, clinical testing, and commercialization of innovative medical products like non-injectable insulin. The region is a hub for technological innovation, which includes advancements in drug delivery systems. Non-injectable insulin methods require sophisticated technology, and North America's innovation ecosystem facilitates the development of these technologies. The pharmaceutical industry in North America is robust, with many companies investing in research and development. These companies have the resources to develop and market non-injectable insulin products, driving growth. North America is often a preferred location for conducting clinical trials due to its diverse population, well-established regulatory framework, and skilled medical professionals. Clinical trials are crucial for demonstrating the safety and efficacy of new medical products. Public awareness campaigns and healthcare initiatives help educate patients about various treatment options. As patients become more aware of non-injectable insulin methods, they are likely to express interest, driving demand. Patient preferences for non-injectable insulin options align with the convenience and ease of use offered by these methods. Meeting patient preferences drives adoption and market growth.

Key Market Players

• Midatech Pharma Plc

• Shreya Life Sciences Pvt. Ltd.

• Boston Therapeutics, Inc.

• Coromed, Inc.

• Diabetology Ltd.

• Emisphere Technologies, Inc.

• Oramed Pharmaceuticals, Inc.

• Diasome Pharmaceuticals, Inc.

• Generex Biotechnology Corp.

• Biodel, Inc.

Report Scope:

In this report, the Global Non-Injectable Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Injectable Insulin Market, By Product:

• Pills
• Sprays
• Others

Non-Injectable Insulin Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Drug Stores

Non-Injectable Insulin Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.

Available Customizations:

• Global Non-Injectable Insulin market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Injectable Insulin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Pills, Sprays, and Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1 By Product
  • 5.3.2 By Distribution Channel
  • 35.3.4 By Region

6. North America Non-Injectable Insulin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Pills, Sprays, and Others)
  • 6.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Injectable Insulin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Non-Injectable Insulin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Non-Injectable Insulin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Distribution Channel

7. Europe Non-Injectable Insulin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (Pills, Sprays, and Others)
  • 7.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Non-Injectable Insulin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Non-Injectable Insulin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Non-Injectable Insulin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Non-Injectable Insulin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Non-Injectable Insulin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (Pills, Sprays, and Others)
  • 8.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Non-Injectable Insulin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Non-Injectable Insulin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Non-Injectable Insulin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Non-Injectable Insulin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Non-Injectable Insulin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Distribution Channel

9. South America Non-Injectable Insulin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (Pills, Sprays, and Others)
  • 9.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Non-Injectable Insulin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Non-Injectable Insulin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Non-Injectable Insulin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Non-Injectable Insulin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (Pills, Sprays, and Others)
  • 10.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Non-Injectable Insulin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Non-Injectable Insulin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Non-Injectable Insulin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Non-Injectable Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Midatech Pharma Plc
  • 15.6.2 Shreya Life Sciences Pvt. Ltd.
  • 15.6.3 Boston Therapeutics, Inc.
  • 15.6.4 Coromed, Inc.
  • 15.6.5 Diabetology Ltd.
  • 15.6.6 Emisphere Technologies, Inc.
  • 15.6.7 Oramed Pharmaceuticals, Inc.
  • 15.6.8 Diasome Pharmaceuticals, Inc.
  • 15.6.9 Generex Biotechnology Corp.
  • 15.6.10 Biodel, Inc.

16. Strategic Recommendations